Company profile
eXoZymes, Inc.
NASDAQ: EXOZ · Healthcare · Biotechnology
PublicHQ Monrovia, NVCIK 0002010788Reports USD
#1063 of 1,418 Healthcare companies by revenue
EA Score
24DFH 25DQ 20GM —SS 37
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$9.2M
Employees
32
as of 2026-08-18
Market cap
$59.4M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$70.1k$70.1k2024
Net income-$9.2M-$9.2M2025
Operating income-$9.7M-$9.7M2025
Total assets$6.0M$6.0M2025
Liabilities$2.6M$2.6M2025
Equity$3.4M$3.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is eXoZymes, Inc.’s revenue?
eXoZymes, Inc. booked $70.1k in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -13071.0% net margin.
Peers · Healthcare
Paranovus Entertainment Technology Ltd.——PAVmed Inc.40DExlites Holdings International, Inc.54DOncotelic Therapeutics, Inc.46DMYND Life Sciences Inc.——Vivos Inc.48DKey facts
CEOMichael Heltzen
SectorHealthcare
IndustryBiotechnology
HeadquartersMonrovia, NV
ExchangeNASDAQ: EXOZ
Employees32
IPO date2024-11-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.